dulaglutide vs Semaglutide (Rybelsus)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
dulaglutide · Trulicity
Marketed by Eli Lilly
NCT01394952 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial involving 9,901 participants. The hard clinical primary endpoint was met: 594 dulaglutide participants versus 663 placebo participants experienced a composite cardiovascular event, with a hazard ratio of 0.88 (p=0.026).
Next expected readout: April 2027 · NCT07537088 (registry estimate)
Reported efficacy
Change in Hemoglobin A1c (HbA1c) From Baseline (Baseline, Week 36): Change in Hemoglobin A1c (HbA1c) From Baseline (Baseline, Week 36): Dulaglutide 1.5 mg -1.53 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 3 mg -1.71 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 4.5 mg -1.87 Percentage of HbA1c (Standard Error 0.04) (met)
Result source: NCT03495102
Semaglutide (Rybelsus)
Marketed by Novo Nordisk
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: January 2027 · NCT06050577 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | dulaglutide | Semaglutide (Rybelsus) |
|---|---|---|
| HbA1c, change | -2.0% vs -1.1%−0.9 vs placeboNCT0459162625 other results
| -1.6% vs -0.2%−1.4 vs placeboNCT0410954734 other results
|
| Body weight, change (kg) | -0.8 vs 0.4−1.2 vs placeboNCT0459162618 other results
| -4.2 vs -1.3−2.9 vs placeboNCT0391432639 other results
|
| HbA1c below 7% | 75.9% vs 33.8%+42.1 vs placeboNCT045916268 other results
| —Not posted · NCT07271251 |
| Fasting plasma glucose, change | -2.2 vs -2.4vs Insulin GlargineNCT016485823 other results
| -1.9 vs -0.7−1.2 vs placeboNCT0286341939 other results
|
| 3-point MACE (% with event) | 12% vs 13.4%−1.4 vs placeboNCT013949521 other result
| 12% vs 13.8%−1.8 vs placeboNCT039143261 other result
|
HbA1c, change
- dulaglutide
- -2.0% vs -1.1%−0.9 vs placeboNCT04591626
25 other results
- -1.3% vs -0.5% NCT02597049
- -1.3% vs -0.5% NCT02597049
- -1.2% vs -0.5% NCT02597049
- -1.2% vs -0.5% NCT02597049
- -1.4% vs -0.7% NCT02152371
- -1.4% vs -0.1% NCT01769378
- -1.2% vs -1.1% NCT01621178
- -1.7% vs -1.2% NCT01648582
- -1.5% vs -0.9% NCT01644500
- -1.4% vs -1.4% NCT01624259
- -1.1% vs -1.1% NCT01621178
- -1.3% vs -1.2% NCT01648582
- -1.2% vs -0.9% NCT01644500
- -1.4% vs -0.9% NCT01584232
- -1% vs 0.5% NCT02963766
- -0.5% vs 0.5% NCT02963766
- -0.9% vs -1.7% NCT04255433
- -1.1% vs -1% NCT01621178
- -1.5% vs -0.9% NCT01648582
- -1.1% vs -1% NCT01621178
- -1.0% vs -0.9% NCT01648582
- -1.4% vs -0.4% NCT02973100
- -1.3% vs -0.4% NCT02973100
- -1.2% vs -0.4% NCT02973100
- -1.4% vs 0.1% NCT02750410
- Semaglutide (Rybelsus)
- -1.6% vs -0.2%−1.4 vs placeboNCT04109547
34 other results
- -1.5% vs -0.2% NCT04109547
- -1.1% vs -0.2% NCT04109547
- -0.7% vs -0.1% NCT03914326
- -1% vs -0.3% NCT02692716
- -1.2% vs -0.1% NCT02863419
- -1.2% vs -0.2% NCT03021187
- -0.9% vs -0.2% NCT03021187
- -0.6% vs -0.2% NCT03021187
- -1.5% vs 0.1% NCT03018028
- -1.4% vs 0.1% NCT03018028
- -1% vs 0.1% NCT03018028
- -1.3% vs -0.9% NCT02863328
- -1.2% vs -0.7% NCT02607865
- -1.1% vs -0.7% NCT02607865
- -1% vs -0.7% NCT02607865
- -0.9% vs -0.7% NCT02607865
- -0.6% vs -0.7% NCT02607865
- -0.6% vs -0.7% NCT02607865
- -1.8% vs -1.4% NCT03015220
- -2% vs -1.6% NCT03015220
- -1.4% vs -1.4% NCT03015220
- -1.7% vs -1.6% NCT03015220
- -0.8% vs -1.4% NCT03015220
- -1.1% vs -1.6% NCT03015220
- -1.3% vs -0.8% NCT02849080
- -0.2% vs 0% NCT02849080
- -2.0% vs -0.4% NCT01923181
- -1.8% vs -0.4% NCT01923181
- -1.6% vs -0.4% NCT01923181
- -1.7% vs -0.4% NCT01923181
- -1.6% vs -0.4% NCT01923181
- -1.2% vs -0.4% NCT01923181
- -0.9% vs -0.4% NCT01923181
- -1.2% vs -1.0% NCT05035082
Body weight, change (kg)
- dulaglutide
- -0.8 vs 0.4−1.2 vs placeboNCT04591626
18 other results
- -1.9 vs 0.5 NCT02152371
- -0.9 vs -0.2 NCT01769378
- -2.7 vs 1.6 NCT01621178
- -1.1 vs 1.4 NCT01648582
- -2.8 vs 1.1 NCT01621178
- -1.5 vs 1.0 NCT01648582
- -1.5 vs 0.9 NCT01644500
- -2.9 vs -3.6 NCT01624259
- -1.7 vs 1.6 NCT01621178
- -0.8 vs 1.4 NCT01648582
- -2.0 vs 1.1 NCT01621178
- -0.9 vs 1.0 NCT01648582
- -0.8 vs 0.9 NCT01644500
- -0.5 vs 0.9 NCT01584232
- -4.1 vs -1.6 NCT02973100
- -3.9 vs -1.6 NCT02973100
- -2.8 vs -1.6 NCT02973100
- -0.2 vs -0.3 NCT02750410
- Semaglutide (Rybelsus)
- -4.2 vs -1.3−2.9 vs placeboNCT03914326
39 other results
- -4.2 vs -0.8 NCT02692716
- -4.4 vs -1 NCT02863419
- -3.8 vs 0.5 NCT03021187
- -3.1 vs -1.1 NCT04109547
- -2.2 vs 0.5 NCT03021187
- -2.9 vs -1 NCT03018028
- -0.8 vs -1 NCT03018028
- -2.2 vs -1.1 NCT04109547
- -0.9 vs 0.5 NCT03021187
- -2.4 vs -1.1 NCT03018028
- -1.2 vs -1.1 NCT03018028
- 0 vs -1 NCT03018028
- -1.1 vs -1.1 NCT04109547
- -0.4 vs -1.1 NCT03018028
- -4 vs -3.7 NCT02863328
- -3.5 vs -0.7 NCT02607865
- -3.2 vs -1 NCT02607865
- -3.8 vs -0.5 NCT04017832
- -2.5 vs -0.7 NCT02607865
- -2.8 vs -1 NCT02607865
- -2.9 vs -0.5 NCT04017832
- -1.6 vs -0.7 NCT02607865
- -1.8 vs -1 NCT02607865
- -1.7 vs 1 NCT03015220
- -2.2 vs 0.3 NCT03015220
- -0.9 vs 1 NCT03015220
- -1 vs 0.3 NCT03015220
- 0 vs 1 NCT03015220
- -1.4 vs -0.5 NCT04017832
- -0.1 vs 0.3 NCT03015220
- -2.6 vs -0.9 NCT02849080
- -6.9 vs -1.2 NCT01923181
- -5.9 vs -1.2 NCT01923181
- -8.3 vs -1.2 NCT01923181
- -5.8 vs -1.2 NCT01923181
- -4.9 vs -1.2 NCT01923181
- -2.9 vs -1.2 NCT01923181
- -2.0 vs -1.2 NCT01923181
- -3.9 vs -3.5 NCT05035082
HbA1c below 7%
- dulaglutide
- 75.9% vs 33.8%+42.1 vs placeboNCT04591626
8 other results
- 32.9% vs 29.1% NCT01621178
- 37.5% vs 34.6% NCT01621178
- 33.5% vs 29.1% NCT01621178
- 31.7% vs 34.6% NCT01621178
- 68.2% vs 20% NCT02973100
- 71.2% vs 20% NCT02973100
- 71.2% vs 20% NCT02973100
- 0% vs 47.4% NCT02750410
- Semaglutide (Rybelsus)
- —Not posted · NCT07271251
Fasting plasma glucose, change
- dulaglutide
- -2.2 vs -2.4vs Insulin GlargineNCT01648582
3 other results
- -2.4 vs -2.6 NCT01648582
- -1.5 vs -2.4 NCT01648582
- -1.7 vs -2.6 NCT01648582
- Semaglutide (Rybelsus)
- -1.9 vs -0.7−1.2 vs placeboNCT02863419
39 other results
- -1.6 vs -0.1 NCT03021187
- -1.9 vs -0.2 NCT02906930
- -2.0 vs -0.3 NCT02863419
- -1.6 vs -0.3 NCT02827708
- -1.4 vs 0.5 NCT03021187
- -1.1 vs -0.1 NCT03021187
- -1.5 vs -0.2 NCT02906930
- -1.1 vs 0.5 NCT03021187
- -0.8 vs -0.1 NCT03021187
- -0.9 vs -0.2 NCT02906930
- -0.5 vs 0.5 NCT03021187
- -2.3 vs 0.3 NCT03018028
- -2.4 vs -0.4 NCT03018028
- -1.6 vs 0.3 NCT03018028
- -1.6 vs -0.4 NCT03018028
- -1.1 vs 0.3 NCT03018028
- -1.6 vs -0.4 NCT03018028
- -2.0 vs -2.1 NCT02863328
- -1.8 vs -1.0 NCT02607865
- -2.0 vs -2.1 NCT02863328
- -1.7 vs -0.9 NCT02607865
- -1.6 vs -0.9 NCT02607865
- -2 vs -0.5 NCT04017832
- -1.3 vs -1.0 NCT02607865
- -1.2 vs -0.9 NCT02607865
- -1.1 vs -0.9 NCT02607865
- -2.7 vs -2.2 NCT03015220
- -1.8 vs -0.5 NCT04017832
- -1.0 vs -1.0 NCT02607865
- -0.8 vs -0.9 NCT02607865
- -1.1 vs -0.9 NCT02607865
- -2.2 vs -1.8 NCT03015220
- -2.0 vs -1.8 NCT03015220
- -2.3 vs -2.2 NCT03015220
- -0.9 vs -1.8 NCT03015220
- -1.0 vs -0.5 NCT04017832
- -1.2 vs -2.2 NCT03015220
- -2.4 vs -1.4 NCT02849080
- -0.3 vs 0.0 NCT02849080
3-point MACE (% with event)
- dulaglutide
- 12% vs 13.4%−1.4 vs placeboNCT01394952
1 other result
- 13.1% vs 12.2% NCT04255433
- Semaglutide (Rybelsus)
- 12% vs 13.8%−1.8 vs placeboNCT03914326
1 other result
- 3.8% vs 4.8% NCT02692716
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
10 other shared endpoints and safety
Coverage. dulaglutide: 14 of 14 rows · Semaglutide (Rybelsus): 13 of 14 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | dulaglutide Rows use multiple source trials | Semaglutide (Rybelsus) Rows use multiple source trials |
|---|---|---|
| BMI absolute change · kg | -0.4 vs 0.52 Insulin Glargine kg @ 52wk1.5 mga,b,c NCT01648582 · Phase 3 · registry result, not featured evidence show 1 more dose-0.27 vs 0.52 Insulin Glargine kg @ 52wk0.75 mg NCT01648582 · Phase 3 · registry result, not featured evidence | -1.5 vs -1.4 Empagliflozin 25 mg kg @ 52wk14 mgb,c NCT02863328 · Phase 3 14 other source trials-1.2 vs -0.3 Sitagliptin kg @ 52wk14 mg NCT02607865 · Phase 3 -0.6 vs -0.3 Sitagliptin kg @ 52wk3 mg NCT02607865 · Phase 3 -0.9 vs -0.3 Sitagliptin kg @ 52wk7 mg NCT02607865 · Phase 3 -1.6 vs -0.4 placebo kg @ 52wk14 mg NCT02863419 · Phase 3 -1.4 vs 0.2 placebo kg @ 52wk14 mg NCT03021187 · Phase 3 -0.3 vs 0.2 placebo kg @ 52wk3 mg NCT03021187 · Phase 3 -0.8 vs 0.2 placebo kg @ 52wk7 mg NCT03021187 · Phase 3 -1 vs -0.3 Sitagliptin kg @ 52wk NCT02849080 · Phase 3 · registry result, not featured evidence -1.1 vs -0.4 placebo kg @ 52wk14 mg NCT03018028 · Phase 3 · registry result, not featured evidence 0 vs -0.4 placebo kg @ 52wk3 mg NCT03018028 · Phase 3 · registry result, not featured evidence -0.3 vs -0.4 placebo kg @ 52wk7 mg NCT03018028 · Phase 3 · registry result, not featured evidence -0.6 vs 0.3 Dulaglutide kg @ 52wk14 mg NCT03015220 · Phase 3 · registry result, not featured evidence 0 vs 0.3 Dulaglutide kg @ 52wk3 mg NCT03015220 · Phase 3 · registry result, not featured evidence -0.3 vs 0.3 Dulaglutide kg @ 52wk7 mg NCT03015220 · Phase 3 · registry result, not featured evidence |
| Coronary Revascularization event count · % of participants | 9.4% (n=6579) vs 8% (n=6586) Tirzepatide @ 259wk*1.5 mgb,c,d NCT04255433 · Phase 3 · registry result, not featured evidence · converted to % from 617 participants as posted | 4.1% (n=4825) vs 5.5% (n=4825) placebo @ 265wk*b,c,d NCT03914326 · Phase 3 · converted to % from 200 Participants as posted |
| Fasting Plasma Glucose Change mg/dL absolute change · mg | -34.81 vs -34.25 Liraglutide mg @ 26wk1.5 mg weeklyb,c NCT01624259 · Phase 3 · registry result, not featured evidence | -32.5 vs 0 placebo mg @ 26wk14 mga,b,c NCT04109547 · Phase 3 · registry result, not featured evidence show 2 more doses-32.28 vs 0 placebo mg @ 26wk7 mg NCT04109547 · Phase 3 · registry result, not featured evidence -19.07 vs 0 placebo mg @ 26wk3 mg NCT04109547 · Phase 3 · registry result, not featured evidence |
| HbA1c absolute change · percentage points No placebo or comparator arm | -1.5% (n=383) @ 52wk1.5 mga,b,c NCT04809220 · Phase 3 · registry result, not featured evidence show 1 more dose-1.19% (n=193) @ 52wk0.75 mg NCT04809220 · Phase 3 · registry result, not featured evidence | -1.5% (n=497) @ 52wk14 mg once dailya,b,c NCT04707469 · Phase 3 · registry result, not featured evidence show 5 more doses-0.4% (n=333) @ 52wk14 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence -2.1% (n=492) @ 52wk50 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence -1% (n=339) @ 52wk50 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence -1.9% (n=475) @ 52wk25 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence -0.8% (n=345) @ 52wk25 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence |
| HbA1c Less Than 7% responder rate · % of participants No placebo or comparator arm | 71.48% (n=526) @ 36wk4.5 mga,b,c,e NCT03495102 · Phase 3 show 2 more doses64.68% (n=521) @ 36wk3 mg NCT03495102 · Phase 3 56.98% (n=523) @ 36wk1.5 mg NCT03495102 · Phase 3 | 39.2% (n=536) @ 68wk14 mg once dailya,b,c,e NCT04707469 · Phase 3 · registry result, not featured evidence show 2 more doses58.9% (n=535) @ 68wk50 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence 49.9% (n=535) @ 68wk25 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence |
| HF Hospitalization or Urgent Visit event count · % of participants | 4.3% (n=4949) vs 4.6% (n=4952) placebo*b,c,f NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 213 Participants as posted | 3% (n=4825) vs 3.5% (n=4825) placebo @ 265wk*b,c,f NCT03914326 · Phase 3 · converted to % from 146 Participants as posted |
| Renal Composite event rate · % of participants | 6.7% (n=6579) vs 5.7% (n=6586) Tirzepatide @ 259wk*1.5 mgb,c,d NCT04255433 · Phase 3 · registry result, not featured evidence · converted to % from 442 participants as posted | 2.3% (n=4825) vs 2.7% (n=4825) placebo @ 265wk*b,c,d NCT03914326 · Phase 3 · converted to % from 112 Participants as posted |
| Unstable Angina Hospitalization event count · % of participants | 1.8% (n=4949) vs 1.6% (n=4952) placebo*b,c,f NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 88 Participants as posted | 1.5% (n=4825) vs 1.7% (n=4825) placebo @ 265wk*b,c,f NCT03914326 · Phase 3 · converted to % from 74 Participants as posted |
| Weight percent change · % of baseline | -4.82% (n=6578) vs -11.6% (n=6586) Tirzepatide @ 156wk1.5 mgb,c,g NCT04255433 · Phase 3 · registry result, not featured evidence | -3.12% (n=93) vs -0.7% (n=97) Sitagliptin @ 104wkb,c,g NCT02849080 · Phase 3 · registry result, not featured evidence |
| Weight absolute change · kg No placebo or comparator arm | -0.5 kg @ 52wk1.5 mga,b,c NCT04809220 · Phase 3 · registry result, not featured evidence show 1 more dose-0.2 kg @ 52wk0.75 mg NCT04809220 · Phase 3 · registry result, not featured evidence | -4.4 kg @ 52wk14 mg once dailya,b,c NCT04707469 · Phase 3 · registry result, not featured evidence show 2 more doses-8.3 kg @ 52wk50 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence -7.1 kg @ 52wk25 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence |
| Dropout rate | 0.3%h NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 45 more results4.4% NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3 8.8%4.5 mg NCT03495102 · Phase 3 10.9%3 mg NCT03495102 · Phase 3 9.2%1.5 mg NCT03495102 · Phase 3 —1.5 mg NCT01621178 · Phase 3 —0.75 mg NCT01621178 · Phase 3 3.8%1.5 mg NCT02963766 · Phase 3 —1.5 mg NCT02963766 · Phase 3 —1.5 mg NCT02963766 · Phase 3 3.9%0.75 mg NCT02963766 · Phase 3 —0.75 mg NCT02963766 · Phase 3 —0.75 mg NCT02963766 · Phase 3 —1.5 mg NCT05659537 · Phase 4 · registry result, not featured evidence —0.75 mg NCT05659537 · Phase 4 · registry result, not featured evidence —0.75 mg NCT02750410 · Phase 4 · registry result, not featured evidence —0.75 mg NCT02750410 · Phase 4 · registry result, not featured evidence 2.5%Dulaglutide NCT02750410 · Phase 4 · registry result, not featured evidence — NCT03315780 · Phase 4 · registry result, not featured evidence 2.2%1.5 mg NCT04255433 · Phase 3 · registry result, not featured evidence —1.5 mg NCT04809220 · Phase 3 · registry result, not featured evidence 3.1%0.75 mg NCT04809220 · Phase 3 · registry result, not featured evidence —1.5 mg NCT04591626 · Phase 3 · registry result, not featured evidence · add on 4.9%1.5 mg NCT02597049 · Phase 3 · registry result, not featured evidence 3.5%0.75 mg NCT02597049 · Phase 3 · registry result, not featured evidence 8% NCT02152371 · Phase 3 · registry result, not featured evidence · combination 12.4%1.5 mg NCT01648582 · Phase 3 · registry result, not featured evidence 14.8%0.75 mg NCT01648582 · Phase 3 · registry result, not featured evidence 10.4% NCT01769378 · Phase 3 · registry result, not featured evidence 9%1.5 mg NCT01644500 · Phase 3 · registry result, not featured evidence 9.7%0.75 mg NCT01644500 · Phase 3 · registry result, not featured evidence —1.5 mg weekly NCT01624259 · Phase 3 · registry result, not featured evidence 10%LY2189265 NCT01624259 · Phase 3 · registry result, not featured evidence 9.2%4.5 mg NCT02973100 · Phase 2 · registry result, not featured evidence 5.1%3.0 mg NCT02973100 · Phase 2 · registry result, not featured evidence —1.5 mg NCT02973100 · Phase 2 · registry result, not featured evidence —1.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence —1.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence —0.75 mg NCT01667900 · Phase 1 · registry result, not featured evidence —0.75 mg NCT01667900 · Phase 1 · registry result, not featured evidence —0.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence —0.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence — NCT01458210 · Phase 1 · registry result, not featured evidence · combination —Dulaglutide + Warfarin NCT01432938 · Phase 1 · registry result, not featured evidence · combination —Dulaglutide Alone NCT01432938 · Phase 1 · registry result, not featured evidence · monotherapy 16.7% NCT01436201 · Phase 1 · registry result, not featured evidence · combination | 6.9%14 mgi NCT02906930 · Phase 3 show 39 more results8%7 mg NCT02906930 · Phase 3 3.4%3 mg NCT02906930 · Phase 3 2.7%14 mg NCT02863328 · Phase 3 5.8%14 mg NCT02607865 · Phase 3 6.4%7 mg NCT02607865 · Phase 3 7.1%3 mg NCT02607865 · Phase 3 2.8%14 mg NCT02863419 · Phase 3 3.1%14 mg NCT02827708 · Phase 3 3.3%14 mg NCT03021187 · Phase 3 4.9%7 mg NCT03021187 · Phase 3 5.4%3 mg NCT03021187 · Phase 3 1.5% NCT03914326 · Phase 3 0.3% NCT02692716 · Phase 3 11.8% NCT05035082 · Phase 4 · registry result, not featured evidence 5.4%14 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence 5.6%50 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence 8.4%25 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence 7.2%14 mg NCT04017832 · Phase 3 · registry result, not featured evidence 5%7 mg NCT04017832 · Phase 3 · registry result, not featured evidence 4.4%3 mg NCT04017832 · Phase 3 · registry result, not featured evidence 4.6%14 mg NCT04109547 · Phase 3 · registry result, not featured evidence 3.1%7 mg NCT04109547 · Phase 3 · registry result, not featured evidence 3.1%3 mg NCT04109547 · Phase 3 · registry result, not featured evidence —Oral Semaglutide Flex- Main Phase NCT02849080 · Phase 3 · registry result, not featured evidence —Oral Semaglutide Flex- Sustainabil NCT02849080 · Phase 3 · registry result, not featured evidence —Oral Semaglutide Flex- Switch NCT02849080 · Phase 3 · registry result, not featured evidence 2.1%14 mg NCT03018028 · Phase 3 · registry result, not featured evidence 0%7 mg NCT03018028 · Phase 3 · registry result, not featured evidence 6.1%3 mg NCT03018028 · Phase 3 · registry result, not featured evidence 2.3%14 mg NCT03015220 · Phase 3 · registry result, not featured evidence 1.5%7 mg NCT03015220 · Phase 3 · registry result, not featured evidence 2.3%3 mg NCT03015220 · Phase 3 · registry result, not featured evidence 11.3%40 mg NCT01923181 · Phase 2 · registry result, not featured evidence 11.4%40 mg NCT01923181 · Phase 2 · registry result, not featured evidence 5.7%40 mg NCT01923181 · Phase 2 · registry result, not featured evidence 7.1%20 mg NCT01923181 · Phase 2 · registry result, not featured evidence 2.9%10 mg NCT01923181 · Phase 2 · registry result, not featured evidence 8.6%5 mg NCT01923181 · Phase 2 · registry result, not featured evidence 4.3%2.5 mg NCT01923181 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —h NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 45 more results1.7% NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3 1.6%4.5 mg NCT03495102 · Phase 3 1.1%3 mg NCT03495102 · Phase 3 0.8%1.5 mg NCT03495102 · Phase 3 —1.5 mg NCT01621178 · Phase 3 —0.75 mg NCT01621178 · Phase 3 1.9%1.5 mg NCT02963766 · Phase 3 —1.5 mg NCT02963766 · Phase 3 —1.5 mg NCT02963766 · Phase 3 0%0.75 mg NCT02963766 · Phase 3 —0.75 mg NCT02963766 · Phase 3 —0.75 mg NCT02963766 · Phase 3 —1.5 mg NCT05659537 · Phase 4 · registry result, not featured evidence —0.75 mg NCT05659537 · Phase 4 · registry result, not featured evidence —0.75 mg NCT02750410 · Phase 4 · registry result, not featured evidence —0.75 mg NCT02750410 · Phase 4 · registry result, not featured evidence 1.7%Dulaglutide NCT02750410 · Phase 4 · registry result, not featured evidence — NCT03315780 · Phase 4 · registry result, not featured evidence —1.5 mg NCT04255433 · Phase 3 · registry result, not featured evidence —1.5 mg NCT04809220 · Phase 3 · registry result, not featured evidence 0%0.75 mg NCT04809220 · Phase 3 · registry result, not featured evidence —1.5 mg NCT04591626 · Phase 3 · registry result, not featured evidence · add on 1.4%1.5 mg NCT02597049 · Phase 3 · registry result, not featured evidence 0%0.75 mg NCT02597049 · Phase 3 · registry result, not featured evidence 4% NCT02152371 · Phase 3 · registry result, not featured evidence · combination 2.3%1.5 mg NCT01648582 · Phase 3 · registry result, not featured evidence 4.3%0.75 mg NCT01648582 · Phase 3 · registry result, not featured evidence 4.2% NCT01769378 · Phase 3 · registry result, not featured evidence 2.5%1.5 mg NCT01644500 · Phase 3 · registry result, not featured evidence 0.4%0.75 mg NCT01644500 · Phase 3 · registry result, not featured evidence —1.5 mg weekly NCT01624259 · Phase 3 · registry result, not featured evidence 6%LY2189265 NCT01624259 · Phase 3 · registry result, not featured evidence 2.6%4.5 mg NCT02973100 · Phase 2 · registry result, not featured evidence 1.3%3.0 mg NCT02973100 · Phase 2 · registry result, not featured evidence —1.5 mg NCT02973100 · Phase 2 · registry result, not featured evidence —1.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence —1.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence —0.75 mg NCT01667900 · Phase 1 · registry result, not featured evidence —0.75 mg NCT01667900 · Phase 1 · registry result, not featured evidence —0.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence —0.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence — NCT01458210 · Phase 1 · registry result, not featured evidence · combination —Dulaglutide + Warfarin NCT01432938 · Phase 1 · registry result, not featured evidence · combination —Dulaglutide Alone NCT01432938 · Phase 1 · registry result, not featured evidence · monotherapy 8.3% NCT01436201 · Phase 1 · registry result, not featured evidence · combination | —14 mgi NCT02906930 · Phase 3 show 39 more results—7 mg NCT02906930 · Phase 3 —3 mg NCT02906930 · Phase 3 —14 mg NCT02863328 · Phase 3 —14 mg NCT02607865 · Phase 3 —7 mg NCT02607865 · Phase 3 —3 mg NCT02607865 · Phase 3 —14 mg NCT02863419 · Phase 3 —14 mg NCT02827708 · Phase 3 —14 mg NCT03021187 · Phase 3 —7 mg NCT03021187 · Phase 3 —3 mg NCT03021187 · Phase 3 — NCT03914326 · Phase 3 — NCT02692716 · Phase 3 — NCT05035082 · Phase 4 · registry result, not featured evidence —14 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence —50 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence —25 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence —14 mg NCT04017832 · Phase 3 · registry result, not featured evidence —7 mg NCT04017832 · Phase 3 · registry result, not featured evidence —3 mg NCT04017832 · Phase 3 · registry result, not featured evidence —14 mg NCT04109547 · Phase 3 · registry result, not featured evidence —7 mg NCT04109547 · Phase 3 · registry result, not featured evidence —3 mg NCT04109547 · Phase 3 · registry result, not featured evidence —Oral Semaglutide Flex- Main Phase NCT02849080 · Phase 3 · registry result, not featured evidence —Oral Semaglutide Flex- Sustainabil NCT02849080 · Phase 3 · registry result, not featured evidence —Oral Semaglutide Flex- Switch NCT02849080 · Phase 3 · registry result, not featured evidence —14 mg NCT03018028 · Phase 3 · registry result, not featured evidence —7 mg NCT03018028 · Phase 3 · registry result, not featured evidence —3 mg NCT03018028 · Phase 3 · registry result, not featured evidence —14 mg NCT03015220 · Phase 3 · registry result, not featured evidence —7 mg NCT03015220 · Phase 3 · registry result, not featured evidence —3 mg NCT03015220 · Phase 3 · registry result, not featured evidence —40 mg NCT01923181 · Phase 2 · registry result, not featured evidence —40 mg NCT01923181 · Phase 2 · registry result, not featured evidence —40 mg NCT01923181 · Phase 2 · registry result, not featured evidence —20 mg NCT01923181 · Phase 2 · registry result, not featured evidence —10 mg NCT01923181 · Phase 2 · registry result, not featured evidence —5 mg NCT01923181 · Phase 2 · registry result, not featured evidence —2.5 mg NCT01923181 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 40.3%h NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 45 more results5% NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3 6.2%4.5 mg NCT03495102 · Phase 3 7.3%3 mg NCT03495102 · Phase 3 8.7%1.5 mg NCT03495102 · Phase 3 21.4%1.5 mg NCT01621178 · Phase 3 25.3%0.75 mg NCT01621178 · Phase 3 —1.5 mg NCT02963766 · Phase 3 1.9%1.5 mg NCT02963766 · Phase 3 4%1.5 mg NCT02963766 · Phase 3 —0.75 mg NCT02963766 · Phase 3 2%0.75 mg NCT02963766 · Phase 3 2%0.75 mg NCT02963766 · Phase 3 0%1.5 mg NCT05659537 · Phase 4 · registry result, not featured evidence 0%0.75 mg NCT05659537 · Phase 4 · registry result, not featured evidence 2.5%0.75 mg NCT02750410 · Phase 4 · registry result, not featured evidence 5%0.75 mg NCT02750410 · Phase 4 · registry result, not featured evidence —Dulaglutide NCT02750410 · Phase 4 · registry result, not featured evidence 0% NCT03315780 · Phase 4 · registry result, not featured evidence 31.9%1.5 mg NCT04255433 · Phase 3 · registry result, not featured evidence 3.8%1.5 mg NCT04809220 · Phase 3 · registry result, not featured evidence 3.6%0.75 mg NCT04809220 · Phase 3 · registry result, not featured evidence 5.6%1.5 mg NCT04591626 · Phase 3 · registry result, not featured evidence · add on 3.5%1.5 mg NCT02597049 · Phase 3 · registry result, not featured evidence 2.1%0.75 mg NCT02597049 · Phase 3 · registry result, not featured evidence 6% NCT02152371 · Phase 3 · registry result, not featured evidence · combination 9.3%1.5 mg NCT01648582 · Phase 3 · registry result, not featured evidence 5.8%0.75 mg NCT01648582 · Phase 3 · registry result, not featured evidence 3.8% NCT01769378 · Phase 3 · registry result, not featured evidence 2.5%1.5 mg NCT01644500 · Phase 3 · registry result, not featured evidence 1.6%0.75 mg NCT01644500 · Phase 3 · registry result, not featured evidence 1.7%1.5 mg weekly NCT01624259 · Phase 3 · registry result, not featured evidence —LY2189265 NCT01624259 · Phase 3 · registry result, not featured evidence 3.9%4.5 mg NCT02973100 · Phase 2 · registry result, not featured evidence 8.9%3.0 mg NCT02973100 · Phase 2 · registry result, not featured evidence 3.7%1.5 mg NCT02973100 · Phase 2 · registry result, not featured evidence 0%1.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence 0%1.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence 0%0.75 mg NCT01667900 · Phase 1 · registry result, not featured evidence 0%0.75 mg NCT01667900 · Phase 1 · registry result, not featured evidence 0%0.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence 9.1%0.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence 0% NCT01458210 · Phase 1 · registry result, not featured evidence · combination 0%Dulaglutide + Warfarin NCT01432938 · Phase 1 · registry result, not featured evidence · combination 0%Dulaglutide Alone NCT01432938 · Phase 1 · registry result, not featured evidence · monotherapy 0% NCT01436201 · Phase 1 · registry result, not featured evidence · combination | 1.1%14 mgi NCT02906930 · Phase 3 show 39 more results1.7%7 mg NCT02906930 · Phase 3 2.9%3 mg NCT02906930 · Phase 3 6.6%14 mg NCT02863328 · Phase 3 9.5%14 mg NCT02607865 · Phase 3 10.1%7 mg NCT02607865 · Phase 3 13.7%3 mg NCT02607865 · Phase 3 10.9%14 mg NCT02863419 · Phase 3 10.4%14 mg NCT02827708 · Phase 3 6.6%14 mg NCT03021187 · Phase 3 10.5%7 mg NCT03021187 · Phase 3 13.6%3 mg NCT03021187 · Phase 3 47.9% NCT03914326 · Phase 3 18.9% NCT02692716 · Phase 3 10.2% NCT05035082 · Phase 4 · registry result, not featured evidence 9.9%14 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence 8.2%50 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence 10.7%25 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence 3%14 mg NCT04017832 · Phase 3 · registry result, not featured evidence 3.1%7 mg NCT04017832 · Phase 3 · registry result, not featured evidence 4.4%3 mg NCT04017832 · Phase 3 · registry result, not featured evidence 3.9%14 mg NCT04109547 · Phase 3 · registry result, not featured evidence 7.7%7 mg NCT04109547 · Phase 3 · registry result, not featured evidence 4.6%3 mg NCT04109547 · Phase 3 · registry result, not featured evidence 9.5%Oral Semaglutide Flex- Main Phase NCT02849080 · Phase 3 · registry result, not featured evidence 14.2%Oral Semaglutide Flex- Sustainabil NCT02849080 · Phase 3 · registry result, not featured evidence 9%Oral Semaglutide Flex- Switch NCT02849080 · Phase 3 · registry result, not featured evidence 0%14 mg NCT03018028 · Phase 3 · registry result, not featured evidence 6.1%7 mg NCT03018028 · Phase 3 · registry result, not featured evidence 4.1%3 mg NCT03018028 · Phase 3 · registry result, not featured evidence 5.4%14 mg NCT03015220 · Phase 3 · registry result, not featured evidence 3%7 mg NCT03015220 · Phase 3 · registry result, not featured evidence 6.9%3 mg NCT03015220 · Phase 3 · registry result, not featured evidence 1.4%40 mg NCT01923181 · Phase 2 · registry result, not featured evidence 7.1%40 mg NCT01923181 · Phase 2 · registry result, not featured evidence 4.3%40 mg NCT01923181 · Phase 2 · registry result, not featured evidence 0%20 mg NCT01923181 · Phase 2 · registry result, not featured evidence 2.9%10 mg NCT01923181 · Phase 2 · registry result, not featured evidence 2.9%5 mg NCT01923181 · Phase 2 · registry result, not featured evidence 1.4%2.5 mg NCT01923181 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | h nausea 14.9% (placebo 5.4%) diarrhoea 13.5% (placebo 8.8%) nasopharyngitis 11.4% (placebo 10.8%) NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 41 more resultsnasopharyngitis 27.1% diarrhoea 12.2% nausea 9.4% NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3 1.5 mg diarrhoea 21.2% (placebo 13.7%) headache 15.4% (placebo 9.8%) nausea 15.4% (placebo 7.8%) NCT02963766 · Phase 3 1.5 mg diarrhoea 12% (placebo 13.7%) nausea 12% (placebo 7.8%) abdominal pain upper 10% (placebo 7.8%) NCT02963766 · Phase 3 0.75 mg vomiting 17.6% (placebo 3.9%) diarrhoea 15.7% (placebo 13.7%) headache 13.7% (placebo 9.8%) NCT02963766 · Phase 3 0.75 mg headache 10.2% (placebo 9.8%) vomiting 8.2% (placebo 3.9%) abdominal pain 6.1% (placebo 5.9%) NCT02963766 · Phase 3 1.5 mg gastritis 14.3% dyslipidaemia 9.5% nausea 9.5% NCT05659537 · Phase 4 · registry result, not featured evidence 0.75 mg anaemia 21.4% gastritis 14.3% dyslipidaemia 7.1% NCT05659537 · Phase 4 · registry result, not featured evidence 0.75 mg nasopharyngitis 15.8% (placebo 30.8%) abdominal discomfort 8.3% (placebo 12.8%) constipation 6.7% (placebo 12.8%) NCT02750410 · Phase 4 · registry result, not featured evidence 0.75 mg nasopharyngitis 28.3% (placebo 30.8%) constipation 10.8% (placebo 12.8%) abdominal discomfort 9.2% (placebo 12.8%) NCT02750410 · Phase 4 · registry result, not featured evidence influenza 16.7% (placebo 0%) decreased appetite 8.3% (placebo 0%) diarrhoea 8.3% (placebo 8.3%) NCT03315780 · Phase 4 · registry result, not featured evidence 1.5 mg nausea 22.3% diarrhoea 18.9% covid-19 15.1% NCT04255433 · Phase 3 · registry result, not featured evidence 1.5 mg constipation 12.5% diarrhoea 10.2% pyrexia 10% NCT04809220 · Phase 3 · registry result, not featured evidence 0.75 mg constipation 8.7% nasopharyngitis 8.7% covid-19 8.2% NCT04809220 · Phase 3 · registry result, not featured evidence 1.5 mg decreased appetite 22.2% (placebo 4.1%) diabetic nephropathy 13.9% (placebo 15%) diarrhoea 13.2% (placebo 8.2%) NCT04591626 · Phase 3 · registry result, not featured evidence · add on 1.5 mg nausea 14.8% (placebo 3.6%) back pain 9.2% (placebo 7.1%) viral upper respiratory tract infection 6.3% (placebo 7.9%) NCT02597049 · Phase 3 · registry result, not featured evidence 0.75 mg diarrhoea 9.9% (placebo 2.9%) back pain 8.5% (placebo 7.1%) viral upper respiratory tract infection 5.7% (placebo 7.9%) NCT02597049 · Phase 3 · registry result, not featured evidence nausea 12% (placebo 1.3%) diarrhoea 11.3% (placebo 4%) upper respiratory tract infection 7.3% (placebo 6.7%) NCT02152371 · Phase 3 · registry result, not featured evidence · combination 1.5 mg hyperlipidaemia 17.8% diarrhoea 16.7% lipase increased 10.5% NCT01648582 · Phase 3 · registry result, not featured evidence 0.75 mg hyperlipidaemia 19.5% diarrhoea 10.9% hypertension 10.9% NCT01648582 · Phase 3 · registry result, not featured evidence nausea 10.5% (placebo 0%) diarrhoea 8.4% (placebo 0%) eructation 5.9% (placebo 0%) NCT01769378 · Phase 3 · registry result, not featured evidence 1.5 mg diarrhoea 17.2% hyperlipidaemia 11.1% nausea 10.2% NCT01644500 · Phase 3 · registry result, not featured evidence 0.75 mg hyperlipidaemia 12.1% diarrhoea 7.3% lipase increased 5.6% NCT01644500 · Phase 3 · registry result, not featured evidence 1.5 mg weekly nausea 20.4% diarrhoea 12% dyspepsia 8% NCT01624259 · Phase 3 · registry result, not featured evidence 4.5 mg nausea 30.3% (placebo 4.9%) diarrhoea 21.1% (placebo 11.1%) vomiting 13.2% (placebo 4.9%) NCT02973100 · Phase 2 · registry result, not featured evidence 3.0 mg nausea 25.3% (placebo 4.9%) diarrhoea 22.8% (placebo 11.1%) decreased appetite 16.5% (placebo 1.2%) NCT02973100 · Phase 2 · registry result, not featured evidence 1.5 mg nausea 22.2% (placebo 4.9%) diarrhoea 11.1% (placebo 11.1%) vomiting 11.1% (placebo 4.9%) NCT02973100 · Phase 2 · registry result, not featured evidence 1.5 mg decreased appetite 18.2% (placebo 0%) abdominal discomfort 9.1% (placebo 6.3%) blood pressure decreased 9.1% (placebo 0%) NCT01667900 · Phase 1 · registry result, not featured evidence 1.5 mg abdominal discomfort 10% (placebo 6.3%) decreased appetite 10% (placebo 0%) nausea 10% (placebo 0%) NCT01667900 · Phase 1 · registry result, not featured evidence 0.75 mg abdominal discomfort 9.1% (placebo 6.3%) nausea 9.1% (placebo 0%) vomiting 9.1% (placebo 0%) NCT01667900 · Phase 1 · registry result, not featured evidence 0.75 mg decreased appetite 18.2% (placebo 0%) abdominal discomfort 9.1% (placebo 6.3%) abdominal distension 9.1% (placebo 0%) NCT01667900 · Phase 1 · registry result, not featured evidence 0.5 mg abdominal discomfort 0% (placebo 6.3%) abdominal distension 0% (placebo 0%) abdominal pain 0% (placebo 0%) NCT01667900 · Phase 1 · registry result, not featured evidence 0.5 mg decreased appetite 18.2% (placebo 0%) abdominal discomfort 9.1% (placebo 6.3%) abdominal pain 9.1% (placebo 0%) NCT01667900 · Phase 1 · registry result, not featured evidence headache 41.2% nausea 41.2% vomiting 35.3% NCT01458210 · Phase 1 · registry result, not featured evidence · combination diarrhoea 8% haemorrhoids 4% injection site pain 4% NCT01432938 · Phase 1 · registry result, not featured evidence · combination vomiting 11.5% decreased appetite 7.7% headache 7.7% NCT01432938 · Phase 1 · registry result, not featured evidence · monotherapy gastrooesophageal reflux disease 33.3% atrioventricular block first degree 28.6% headache 28.6% NCT01436201 · Phase 1 · registry result, not featured evidence · combination | 14 mgi nausea 16% (placebo 5.6%) vomiting 6.9% (placebo 2.2%) decreased appetite 5.1% (placebo 0.6%) NCT02906930 · Phase 3 show 38 more results7 mg nasopharyngitis 6.3% (placebo 3.4%) headache 5.7% (placebo 5.1%) diarrhoea 5.1% (placebo 2.2%) NCT02906930 · Phase 3 3 mg diarrhoea 8.6% (placebo 2.2%) nausea 8% (placebo 5.6%) nasopharyngitis 5.7% (placebo 3.4%) NCT02906930 · Phase 3 14 mg nausea 19.3% (placebo 3.5%) diarrhoea 15.1% (placebo 7.7%) nasopharyngitis 14.4% (placebo 10.6%) NCT02863419 · Phase 3 14 mg nausea 19% (placebo 7.5%) constipation 11.7% (placebo 3.7%) vomiting 11.7% (placebo 1.2%) NCT02827708 · Phase 3 14 mg nausea 22.7% (placebo 7.1%) diarrhoea 14.4% (placebo 6%) decreased appetite 12.7% (placebo 1.1%) NCT03021187 · Phase 3 7 mg nausea 16.6% (placebo 7.1%) diarrhoea 12.2% (placebo 6%) nasopharyngitis 11.6% (placebo 14.7%) NCT03021187 · Phase 3 3 mg nasopharyngitis 14.7% (placebo 14.7%) nausea 11.4% (placebo 7.1%) diarrhoea 8.7% (placebo 6%) NCT03021187 · Phase 3 diabetic retinopathy 19.5% (placebo 19.3%) covid-19 15.7% (placebo 16.1%) nausea 7.1% (placebo 1.3%) NCT03914326 · Phase 3 14 mg once daily nausea 18% diarrhoea 12.4% covid-19 11.8% NCT04707469 · Phase 3 · registry result, not featured evidence 50 mg once daily nausea 27.3% vomiting 18.2% diarrhoea 14.2% NCT04707469 · Phase 3 · registry result, not featured evidence 25 mg once daily nausea 27.2% vomiting 17% diarrhoea 12.9% NCT04707469 · Phase 3 · registry result, not featured evidence 14 mg diarrhoea 13.3% nausea 12.2% decreased appetite 9.4% NCT04017832 · Phase 3 · registry result, not featured evidence 7 mg nausea 10.9% diarrhoea 8.9% decreased appetite 8.4% NCT04017832 · Phase 3 · registry result, not featured evidence 3 mg nausea 10% diarrhoea 8.3% upper respiratory tract infection 7.2% NCT04017832 · Phase 3 · registry result, not featured evidence 14 mg decreased appetite 10.9% (placebo 0%) diarrhoea 9.3% (placebo 1.5%) upper respiratory tract infection 7% (placebo 4.6%) NCT04109547 · Phase 3 · registry result, not featured evidence 7 mg diarrhoea 9.2% (placebo 1.5%) upper respiratory tract infection 9.2% (placebo 4.6%) lipase increased 8.5% (placebo 0%) NCT04109547 · Phase 3 · registry result, not featured evidence 3 mg upper respiratory tract infection 8.5% (placebo 4.6%) lipase increased 5.4% (placebo 0%) nausea 4.6% (placebo 1.5%) NCT04109547 · Phase 3 · registry result, not featured evidence nausea 20.9% nasopharyngitis 10.3% headache 9.9% NCT02849080 · Phase 3 · registry result, not featured evidence nausea 22.9% nasopharyngitis 13.4% diarrhoea 11.5% NCT02849080 · Phase 3 · registry result, not featured evidence nausea 17% diarrhoea 10% nasopharyngitis 7% NCT02849080 · Phase 3 · registry result, not featured evidence 14 mg nasopharyngitis 18.8% (placebo 28.6%) constipation 12.5% (placebo 6.1%) decreased appetite 12.5% (placebo 0%) NCT03018028 · Phase 3 · registry result, not featured evidence 7 mg nasopharyngitis 16.3% (placebo 28.6%) constipation 12.2% (placebo 6.1%) nausea 10.2% (placebo 2%) NCT03018028 · Phase 3 · registry result, not featured evidence 3 mg nasopharyngitis 20.4% (placebo 28.6%) constipation 10.2% (placebo 6.1%) periarthritis 10.2% (placebo 4.1%) NCT03018028 · Phase 3 · registry result, not featured evidence 14 mg nasopharyngitis 30% constipation 15.4% nausea 9.2% NCT03015220 · Phase 3 · registry result, not featured evidence 7 mg nasopharyngitis 29.5% constipation 12.1% decreased appetite 9.1% NCT03015220 · Phase 3 · registry result, not featured evidence 3 mg nasopharyngitis 26% constipation 9.2% influenza 6.9% NCT03015220 · Phase 3 · registry result, not featured evidence 40 mg nausea 33.8% (placebo 1.4%) vomiting 19.7% (placebo 4.2%) decreased appetite 14.1% (placebo 1.4%) NCT01923181 · Phase 2 · registry result, not featured evidence 40 mg nausea 35.7% (placebo 1.4%) vomiting 22.9% (placebo 4.2%) diarrhoea 17.1% (placebo 9.9%) NCT01923181 · Phase 2 · registry result, not featured evidence 40 mg nausea 32.9% (placebo 1.4%) diarrhoea 20% (placebo 9.9%) vomiting 15.7% (placebo 4.2%) NCT01923181 · Phase 2 · registry result, not featured evidence 20 mg nausea 35.7% (placebo 1.4%) diarrhoea 20% (placebo 9.9%) vomiting 17.1% (placebo 4.2%) NCT01923181 · Phase 2 · registry result, not featured evidence 10 mg nausea 33.3% (placebo 1.4%) diarrhoea 23.2% (placebo 9.9%) vomiting 20.3% (placebo 4.2%) NCT01923181 · Phase 2 · registry result, not featured evidence 5 mg nausea 14.3% (placebo 1.4%) headache 12.9% (placebo 5.6%) diarrhoea 10% (placebo 9.9%) NCT01923181 · Phase 2 · registry result, not featured evidence 2.5 mg nausea 12.9% (placebo 1.4%) nasopharyngitis 8.6% (placebo 12.7%) diarrhoea 7.1% (placebo 9.9%) NCT01923181 · Phase 2 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 259 weeks versus 265 weeks.
- eAssessment timepoints differ: 36 weeks versus 68 weeks.
- fThe assessment timepoint is not available for both results.
- gAssessment timepoints differ: 156 weeks versus 104 weeks.
- hPopulation comparability has not been reviewed for 44 of these studies.
- iPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
dulaglutide
show 4 more results
show 8 more results
show 3 more results
show 1 more result
show 2 more results
show 4 more results
show 3 more results
show 3 more results
+ 51 further endpoints in the CSV export.
Semaglutide (Rybelsus)
show 11 more results
show 9 more results
show 36 more results
show 36 more results
show 49 more results
show 10 more results
show 2 more results
show 11 more results
show 10 more results
show 10 more results
show 10 more results
show 36 more results
+ 114 further endpoints in the CSV export.
Atherosclerotic Cardiovascular Disease
Shared mechanism: GLP-1 receptor · full Atherosclerotic Cardiovascular Disease pipeline
dulaglutide · Trulicity
Marketed by Eli Lilly
NCT01394952 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial involving 9,901 participants. The hard clinical primary endpoint was met: 594 dulaglutide participants versus 663 placebo participants experienced a composite cardiovascular event, with a hazard ratio of 0.88 (p=0.026).
Next expected readout: December 2030 · NCT07282041 (registry estimate)
Reported efficacy
Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Dulaglutide 594/4949 vs Placebo 663/4952 (met)
Result source: NCT01394952
Semaglutide (Rybelsus)
Marketed by Novo Nordisk
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: August 2029 · NCT07254572 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Atherosclerotic Cardiovascular Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | dulaglutide | Semaglutide (Rybelsus) |
|---|---|---|
| LDL-C, % change | —Trial running · NCT07282041 | —Not reported |
| Non-HDL-C, % change | —Trial running · NCT07282041 | —Not reported |
| ApoB, % change | —Trial running · NCT07282041 | —Not reported |
| Lp(a), % change | —Trial running · NCT07282041 | —Not reported |
| 3-point MACE (% with event) | —Trial running · NCT07282041 | —Not reported |
LDL-C, % change
- dulaglutide
- —Trial running · NCT07282041
- Semaglutide (Rybelsus)
- —Not reported
Non-HDL-C, % change
- dulaglutide
- —Trial running · NCT07282041
- Semaglutide (Rybelsus)
- —Not reported
ApoB, % change
- dulaglutide
- —Trial running · NCT07282041
- Semaglutide (Rybelsus)
- —Not reported
Lp(a), % change
- dulaglutide
- —Trial running · NCT07282041
- Semaglutide (Rybelsus)
- —Not reported
3-point MACE (% with event)
- dulaglutide
- —Trial running · NCT07282041
- Semaglutide (Rybelsus)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Semaglutide (Rybelsus): no structured comparison results are available for Atherosclerotic Cardiovascular Disease.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: dulaglutide's landscape · Semaglutide (Rybelsus)'s landscape